China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the submission of a market filing for its in-house developed 13-valent pneumococcal conjugate vaccine to the National Medical Products Administration (NMPA).
Streptococcus pneumoniae disease is a high-priority target for vaccine prevention efforts. The 13-valent pneumococcal conjugate vaccine is designed for infants and children aged 6 weeks to 5 years, aiming to prevent invasive diseases caused by 13 serotypes of Streptococcus pneumoniae included in the vaccine, such as bacteremic pneumonia, meningitis, sepsis, and bacteremia. The global shortage of the 13-valent pneumococcal conjugate vaccine is estimated at 180 million doses, according to calculations by authoritative institutions, a gap that cannot be filled by the current three global manufacturers. In China, the market size for the 13-valent pneumococcal conjugate vaccine is projected to reach RMB 35 billion (USD 4.92 billion) by 2030.- Flcube.com
